Sophia Genetics announced partnerships with Complete Genomics and Element Biosciences to integrate its AI analytics into their sequencing platforms for cancer profiling and rare disease workflows, creating sample‑to‑report pipelines for MSK‑IMPACT, MSK‑ACCESS and other tests. The collaborations aim to shorten turnaround times and scale cancer genomic profiling in clinical labs. Separately, CMS granted Medicare coverage for Personalis’ NeXT Personal MRD assay in breast cancer surveillance, approving reimbursement for up to six years for eligible beneficiaries. Personalis framed the decision as validation of tumor‑informed whole‑genome sequencing approaches and a step toward broader clinical adoption of MRD monitoring. Together these moves signal payer and vendor convergence around NGS‑driven oncology diagnostics, with implications for trial enrollment, precision therapy selection, and downstream commercial and lab workflows.